Exciting clinical trial results with Medigrowth CBD highlight our commitment to evidence-based medicines. We're dedicated to improving lives for those with chronic health issues & with big plans ahead, we're ready to scale & make an even greater impact.
Product / Service Details
Global markets, multiple revenue channels & exponential industry growth
Medigrowth is an Australian company offering pharmaceutical-grade medicinal cannabis, including CBD, THC oils, and dried cannabis flower. Quality-assured and lab-tested, we aim to improve patient lives. Over 1 million patients have accessed medicinal cannabis since legalisation, with significant year-on-year growth. We plan to expand our product portfolio, export products, and introduce our veterinary division to drive growth. With active clinical trials, we're focused on accessing global pharmaceutical markets.
Business Model
Summary
FULLY LICENCED OPERATIONS A company with strong medical university links, growing revenue and long-term vision. Proven delivery and ready to scale - 1200% average YOY sales growth - FY21-24
Description
Immediate, mid, and long-term cannabis opportunities: Fully operational Medigrowth Distribution Centre - Revenue from selling Medigrowth CBD & THC products to pharmacies, distributors, clinics & via telehealth www.haiku.health Active clinical trial programme supports plans for registration pathways & global market entry. Medigrowth Centre of Excellence - Proposed manufacturing facility & co-location within a University innovation precinct. (Additional funding required). Veterinary division launch to drive revenue through CBD solutions for pets. kindredcbd.com.au.
Mission & Objectives
Mission
Medigrowth's mission is to develop and commercialise registered cannabinoid medicines for global distribution. In doing so, we have the potential to positively impact the lives of countless people who are living with chronic health conditions.
Business Objectives
The Medigrowth mission began with the simple pursuit of improving lives & we are grounded in pursuit of excellence with integrity. Our clinical trial plans are focused on autism, oncology & mental health - and our 4 year observational trial intends to supply valuable data. Our objectives are already actioned with real world endeavour. We aim to rapidly grow revenue, further develop clinical trials & pursue product registrations for global markets. Through innovation, collaboration & research, we aim to help patients & position Medigrowth as a key global brand.
Industry
Summary
A global opportunity. The medicinal cannabis industry is one of the fastest growing industries globally, as an increasing number of countries legalise the medicinal use of cannabis. Over 50 countries across the globe have a legalised cannabis framework.
Description
The global cannabis market is estimated to be valued at $127 Billion by 2028 with CAGR Value of 26%. Market growth is driven by the growing legalisation of medical cannabis; increasing medicinal application of cannabis & rising public awareness & acceptance. Medicinal cannabis is widely used for treating patients suffering from conditions such as chronic pain, depression, anxiety, cancer, arthritis, epilepsy, autism & Parkinson's disease. The opportunity for clinically validated & registered cannabinoid medicines for mainstream treatment of more health conditions cannot be overstated.
